Janssen Submits First Clinical Application in China for Novel RSV Fusion Protein Inhibitor JNJ-53718678

Source: Pharmaceutical Perspectives

According to the public information on the website of the Center for Drug Evaluation (CDE) under China’s National Medical Products Administration, Johnson & Johnson submitted a clinical trial application for the oral suspension JNJ-53718678 in China, which was accepted by the CDE on July 17. JNJ-53718678 is a novel human respiratory syncytial virus (RSV) fusion protein inhibitor developed by Janssen, a subsidiary of Johnson & Johnson, and has the potential to treat respiratory syncytial virus infections. Globally, JNJ-53718678 is in Phase 2 clinical development, marking its first clinical trial application in China.

Source: CDE Official Website

Respiratory syncytial virus (RSV) is a leading cause of pneumonia and bronchiolitis in young children and the elderly. In addition to developing preventive vaccines, another research and development strategy for combating RSV-induced diseases is to block viral entry into respiratory tract cells. The RSV fusion protein is a viral surface glycoprotein that plays a critical role in the fusion of RSV with target cells and subsequent cellular entry. The surface of RSV is enveloped by two glycoproteins: the attachment glycoprotein (G) and the fusion glycoprotein (F). Studies have shown that the fusion glycoprotein (F) is essential for RSV entry into cells, making it an ideal target for researchers developing RSV fusion protein inhibitors.

JNJ-53718678 is an oral RSV fusion protein inhibitor developed by Janssen Pharmaceuticals. It specifically targets and binds to the viral surface fusion protein, inhibiting RSV fusion protein-mediated fusion with the host cell membrane and thereby preventing viral entry. This mechanism inhibits RSV replication, reduces viral load, and consequently decreases disease severity.

Information on the ClinicalTrials.gov website indicates that Janssen has registered 15 Phase I or II clinical studies on JNJ-53718678, some of which have been completed. According to the results of a Phase I clinical trial conducted in healthy subjects previously released by the company, JNJ-53718678 demonstrated good tolerability.

Currently, Janssen is conducting multiple clinical trials on JNJ-53718678. One of these is a randomized, double-blind, placebo-controlled Phase 2 clinical trial designed to evaluate the clinical outcomes, antiviral activity, safety, tolerability, and pharmacokinetics of JNJ-53718678 in adult and adolescent hematopoietic stem cell transplant recipients with respiratory syncytial virus (RSV) upper respiratory tract infections. Another is a Phase 1 clinical study aimed at assessing the impact of mild, moderate, and severe hepatic impairment on the pharmacokinetics of JNJ-53718678.

▽Follow [WuXi AppTecDe】WeChat Official Account